Analysts Set Expectations for SLNO FY2026 Earnings

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Investment analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Soleno Therapeutics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska expects that the company will post earnings per share of $1.22 for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $123.00 target price on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.19.

Other equities analysts have also recently issued reports about the stock. Robert W. Baird lifted their target price on shares of Soleno Therapeutics from $102.00 to $105.00 and gave the company an “outperform” rating in a report on Thursday, May 8th. Laidlaw lifted their target price on shares of Soleno Therapeutics from $75.00 to $105.00 and gave the company a “buy” rating in a report on Thursday, March 27th. Piper Sandler boosted their price objective on shares of Soleno Therapeutics from $93.00 to $145.00 and gave the company an “overweight” rating in a research note on Thursday, April 24th. UBS Group set a $105.00 price objective on shares of Soleno Therapeutics in a research note on Thursday, March 27th. Finally, Guggenheim boosted their price objective on shares of Soleno Therapeutics from $81.00 to $97.00 and gave the company a “buy” rating in a research note on Thursday, May 8th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Soleno Therapeutics has an average rating of “Buy” and a consensus target price of $106.78.

Soleno Therapeutics Stock Up 2.7%

Shares of NASDAQ SLNO opened at $79.80 on Tuesday. The stock has a market cap of $4.02 billion, a PE ratio of -24.04 and a beta of -2.69. Soleno Therapeutics has a 52-week low of $36.93 and a 52-week high of $80.99. The business has a 50-day moving average price of $72.80 and a 200 day moving average price of $57.46.

Institutional Trading of Soleno Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC lifted its position in shares of Soleno Therapeutics by 27.1% in the fourth quarter. Janus Henderson Group PLC now owns 5,188,265 shares of the company’s stock worth $233,130,000 after purchasing an additional 1,107,166 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its position in shares of Soleno Therapeutics by 58.2% in the first quarter. Adage Capital Partners GP L.L.C. now owns 4,392,696 shares of the company’s stock worth $313,858,000 after purchasing an additional 1,616,720 shares in the last quarter. Nantahala Capital Management LLC lifted its position in shares of Soleno Therapeutics by 20.1% in the fourth quarter. Nantahala Capital Management LLC now owns 3,928,966 shares of the company’s stock worth $176,607,000 after purchasing an additional 658,518 shares in the last quarter. Avoro Capital Advisors LLC lifted its position in shares of Soleno Therapeutics by 15.8% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,525,000 shares of the company’s stock worth $113,499,000 after purchasing an additional 344,000 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Soleno Therapeutics by 47.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,400,418 shares of the company’s stock worth $171,510,000 after purchasing an additional 769,700 shares in the last quarter. 97.42% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Soleno Therapeutics

In other news, Director Matthew Pauls sold 5,937 shares of the firm’s stock in a transaction on Friday, March 28th. The stock was sold at an average price of $71.55, for a total transaction of $424,792.35. Following the completion of the sale, the director now directly owns 6,500 shares of the company’s stock, valued at $465,075. This trade represents a 47.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Bhatnagar Anish sold 699,095 shares of the stock in a transaction on Thursday, March 27th. The shares were sold at an average price of $67.62, for a total value of $47,272,803.90. Following the completion of the transaction, the chief executive officer now owns 577,076 shares of the company’s stock, valued at $39,021,879.12. This trade represents a 54.78% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 942,672 shares of company stock worth $64,058,781 over the last ninety days. Company insiders own 12.30% of the company’s stock.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.